GenVec — Shareholder Meeting (June 2011)
21 slides from GenVec's shareholder meeting presentation, Jun 17, 2011
Slide 1: 2011 Annual Stockholders Meeting
2011 Annual Stockholders Meeng
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements herein relang to future financial or business performance, condions or strategies and other financial and business maers, including expectaons regarding future revenues and operang expenses, are forward-looking statements within the meaning of the Private Securies Li
Slide 3: Key Points
Key Points • Stock price – Gap between price and intrinsic value – Execute on the business plan – Educate invesng community • Business model • Upcoming milestones June 15, 2011 Annual Stockholders Meeng 3
Slide 4: GenVec Strategy
GenVec Strategy Build shareholder value by Using differenated, proprietary technology to create superior therapeucs and vaccines that are developed and commercialized through collaboraons June 15, 2011 Annual Stockholders Meeng 4
Slide 5: Collaborations Drive Development
Collaboraons Drive Development Human Therapeucs Human Vaccines Animal Health An Array of Product Programs Generated by GenVec’s Proprietary, Core Technology June 15, 2011 Annual Stockholders Meeng 5
Slide 6: A True Platform
A True Plaorm • Flexible, cost-effecve product discovery – Enables therapeucs and vaccines – Genes used to produce desired proteins – Rapid proof of concept tesng • Product candidates that meet partner’s needs – Address crical problems – Proprietary • Manufacturing, stability and safety advantages J
Slide 7: GenVec Programs
GenVec Programs Human Vaccines Human Therapeucs Animal Health • RSV (NIH) • Hearing Loss & • FMD • Dengue Fever (NMRC Balance Disorders ─ Development & HJF) (Novars) (DHS) • Malaria (USMMVP) • TNFerade for Cancer ─ Commercial • HIV (NIH – VRC) (Merial) • HSV-2 • Swine diseases (Merial) June 15, 2011
Slide 8: Recent Progress
Recent Progress • Hearing loss: Manufacturing of clinical supplies • Dengue fever: New collaboraon and funding • RSV: Partnering efforts iniated • FMD: Commercializaon agreement with Merial • Viral diseases of swine: New Merial agreement June 15, 2011 Annual Stockholders Meeng 8
Slide 9: Key Objectives
Key Objecves Vaccines Therapeucs Animal Health • RSV: Corporate • Advance hearing loss to • FMD: Field safety study collaboraon the clinic (Novars) (DHS) • Dengue fever: Animal • Collaboraon to develop • FMD: Animal tesng data (NMRC) TNFerade (Merial) • Malaria: Lead • Swine diseases: Iniate opmizao
Slide 10: Financial Highlights: Benefits of Collaborations
Financial Highlights Benefits of Collaboraons 2010 2011(proj) Revenues $16.5M $20-22M Cash Burn $10.7M $6-8M Cash (12/31) $35.2M $27-29M June 15, 2011 Annual Stockholders Meeng 10
Slide 11: Hearing Loss and Balance Disorders
HEARING LOSS AND BALANCE DISORDERS
Slide 12: Overview
Overview • 30- 40 million Americans could benefit from a mechanical device to assist hearing • Our innovave approach is first in class in a major commercial opportunity • Our collaborator, Novars, is a global leader in novel therapeucs • The lead candidate is advancing to the clinic June 15, 2011 An
Slide 13: Novartis Collaboration
Novars Collaboraon • Novars responsible for worldwide development and commercializaon • Up to $213.6M in milestone payments • Royales on product sales • Addional $12.7M development agreement for supply of clinical materials June 15, 2011 Annual Stockholders Meeng 13
Slide 14: The Ear
The Ear June 15, 2011 Annual Stockholders Meeng 14
Slide 15: The Problem: Loss of Sensory Cells
The Problem: Loss of Sensory Cells • Trauma causes loss of sensory cells • Loss of cells causes loss of hearing Mild Loss • Mammals cannot regenerate sensory cells Severe Loss June 15, 2011 Annual Stockholders Meeng 15
Slide 16: Therapeutic Strategy: Generate New Sensory Cells
Therapeuc Strategy: Generate New Sensory Cells • Convert supporng cells to needed sensory cells • Trigger conversion with the natural developmental regulator - Atonal protein • Deliver the Atonal gene to the supporng cells using an adenovector to produce the protein • Atonal protein induces sensory
Slide 17: Regeneration of Hair Cells
Regeneraon of Hair Cells Untreated Treated Izumikawa et al. Nature Medicine, 2005, 11(3): 271-276 June 15, 2011 Annual Stockholders Meeng 17
Slide 18: Regenerated Sensory Cells Attract Nerves
Regenerated Sensory Cells Aract Nerves Neuronal outgrowth New sensory cell Kawamoto et al. J. Neuroscience, 2003, 23(11): 4395-4400 June 15, 2011 Annual Stockholders Meeng 18
Slide 19: Treatment Restores Hearing
Treatment Restores Hearing Deafened Treated Guinea Pig Model Control ABR Threshold (dB SPL) 105 90 75 60 45 30 15 4 8 16 24 Frequency (kHz) Izumikawa et al. Nature Medicine, 2005, 11(3): 271-276 June 15, 2011 Annual Stockholders Meeng 19
Slide 20: Differentiated Vaccines
Differenated Vaccines • Broadly applicable vaccine technology – Suite of vectors for gene delivery – Versale cell lines for vector producon – Smulaon of both arms of immune system • Vaccines that overcome known problems – Respiratory Syncyal Virus (RSV) – Foot and mouth disease (FMD) – Herpes simple
Slide 21: In Summary
In Summary • Sustainable business strategy • Funded product pipeline with many upcoming development milestones • Emerging partnering opportunies • Solid financial posion: Greater than 3 years of operang capital June 15, 2011 Annual Stockholders Meeng 21